Elucidating the specific pharmacological mechanism of action (MOA) of Normally taking place compounds can be complicated. Although Tarselli et al. (60) created the initial de novo synthetic pathway to conolidine and showcased this Normally happening compound properly suppresses responses to both equally chemically induced and inflammation-derived p